ImmunityBio announces preliminary Q1 2026 results with record $44.2 million in net product revenue and approximately $381 million in cash and marketable securities.
https://finviz.com/quote.ashx?t=IBRX&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.